b'IGK MRD Clonality AssayBackgroundCombinations of chemotherapy, radiation therapy and bonerearranged through the random deletion or insertion of marrow transplantation are potentially curative for severalnucleotides within the junctional region, generating specific hematologic malignancies. However, in some patients, occultand unique sequences within each lymphocyte. Cancer cells tumor cells exist and are thought to increase the patientsthat arise from alterations in single lymphoid precursors risk of relapse. 1These subclinical levels of residual leukemiaacquire clonal IGK junctional regions which can be used as are known as minimal residual disease (MRD), and can betumor-specific markers. 2-3evaluated using sensitive assays.MRD detection by Next-Generation Sequencing has The tracking of antigen-receptor gene rearrangementsdemonstrated utility in predicting clinical outcomes for clonality analyses and MRD monitoring can be appliedand in generating clinically actionable results, allowing to virtually all patients. During early B-cell development,early intervention, confirmation of disease status prior to the germline variable (V), constant (C), and joining (J)transplant, and increased confidence in remission status.fragments of the immunoglobulin kappa (IGK) locus become References1.Rezuke WN et al. (1997) Molecular diagnosis of B- and T-cell lymphomas: fundamental principles and clinical applications. Clin Chem 43:1814-23.2.Gazzola A et al. (2014) The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies. Ther Adv Hematol. 5:35-47.3.Gonzlez D et al. (2007) Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood 110:3112-21. 42'